Becton Dickinson Discontinuing Glucose Monitor Development Program
This article was originally published in The Gray Sheet
Becton Dickinson's decision not to introduce a stand-alone blood glucose monitoring product by year-end gives the company extra resources to focus further on its "strategic bullseye" represented by sharps protection, biosciences and insulin delivery.
You may also be interested in...
Becton Dickinson's safety engineered "sharps" program with Kaiser Permanente, announced June 16, signals the initial success of a strategy that is expected to carry the company out of its recent warnings of slower growth.
Legislation introduced in the House May 20 by Reps. Pete Stark (D-Calif.) and Marge Roukema (R-N.J.) would amend the Occupational Safety and Health Administration's bloodborne pathogen standard to require that employers use needleless systems and sharps with engineered safety features to reduce the risk of accidental needlesticks among health care workers.
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.